🇺🇸 Gadoteric Acid Meglumine Salt in United States
10 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 10
Most-reported reactions
- Adrenomegaly — 1 report (10%)
- Ascites — 1 report (10%)
- Diarrhoea — 1 report (10%)
- Granulocytopenia — 1 report (10%)
- Hepatic Cyst — 1 report (10%)
- Neoplasm Progression — 1 report (10%)
- Oedema Peripheral — 1 report (10%)
- Pneumonia — 1 report (10%)
- Pneumonitis — 1 report (10%)
- Renal Cyst — 1 report (10%)
Other Diagnostic Imaging approved in United States
Frequently asked questions
Is Gadoteric Acid Meglumine Salt approved in United States?
Gadoteric Acid Meglumine Salt does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Gadoteric Acid Meglumine Salt in United States?
The Central Hospital of Lishui City is the originator. The local marketing authorisation holder may differ — check the official source linked above.